Stockscreener 앱 받기
0.00
100.00%
-63.48
전일 마감가:
$63.48
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$11.52B
수익:
$4.42B
순이익/손실:
$-413.00M
주가수익비율:
0.00
EPS:
-2.27
순현금흐름:
$99.00M
1주 성능:
-100.00%
1개월 성능:
-100.00%
6개월 성능:
-100.00%
1년 성능:
-100.00%
1일 변동 폭
$0.00
$0.00
1주일 범위
$0.00
$0.00
52주 변동 폭
$0.00
$63.50
Catalent Inc Stock (CTLT) Company Profile
명칭
Catalent Inc
전화
(732) 537-6200
주소
14 SCHOOLHOUSE ROAD, SOMERSET, NJ
CTLT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CTLT
Catalent Inc
|
0.00 | 11.52B | 4.42B | -413.00M | 99.00M | -2.27 |
|
ZTS
Zoetis Inc
|
154.69 | 65.50B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.18 | 46.99B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.23 | 45.96B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.19 | 17.04B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
297.39 | 12.77B | 2.76B | 1.11B | 898.10M | 22.77 |
Catalent Inc Stock (CTLT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-11-16 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2023-09-05 | 업그레이드 | Argus | Hold → Buy |
| 2023-07-20 | 개시 | Wells Fargo | Equal Weight |
| 2023-07-05 | 재개 | JP Morgan | Neutral |
| 2023-06-14 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-05-22 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2023-05-15 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2023-05-08 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2023-04-17 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2023-04-14 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-04-10 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2023-04-03 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2022-12-19 | 다운그레이드 | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2022-11-07 | 다운그레이드 | Argus | Buy → Hold |
| 2022-11-02 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-12-16 | 개시 | Barclays | Overweight |
| 2020-12-10 | 업그레이드 | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2020-06-25 | 개시 | Argus | Buy |
| 2020-04-21 | 개시 | RBC Capital Mkts | Outperform |
| 2020-03-02 | 개시 | Deutsche Bank | Hold |
| 2019-10-17 | 재개 | Stephens | Overweight |
| 2019-08-28 | 다운그레이드 | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2019-06-21 | 업그레이드 | Jefferies | Hold → Buy |
| 2019-04-16 | 업그레이드 | UBS | Neutral → Buy |
| 2018-11-07 | 업그레이드 | First Analysis Sec | Neutral → Outperform |
| 2018-10-09 | 개시 | UBS | Neutral |
| 2018-03-28 | 업그레이드 | KeyBanc Capital Mkts | Sector Weight → Overweight |
| 2018-03-21 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2018-02-06 | 다운그레이드 | Stephens | Overweight → Equal-Weight |
| 2017-09-21 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2017-09-13 | 개시 | Needham | Hold |
| 2017-09-08 | 다운그레이드 | KeyBanc Capital Mkts | Overweight → Sector Weight |
| 2016-12-01 | 개시 | Goldman | Neutral |
| 2016-10-20 | 개시 | KeyBanc Capital Mkts | Overweight |
| 2016-06-21 | 업그레이드 | Wells Fargo | Market Perform → Outperform |
| 2016-06-20 | 업그레이드 | BofA/Merrill | Neutral → Buy |
모두보기
Catalent Inc 주식(CTLT)의 최신 뉴스
Press Release Distribution & PR Platform - ACCESS Newswire
Silexion Partners With Catalent To Advance SIL204 SiRNA Therapy For KRAS-Driven Cancers - Nasdaq
Silexion Therapeutics Enters Strategic Collaboration with Catalent to Advance SIL204 Development for KRAS-Driven Cancers - Nasdaq
Major Breakthrough: Silexion's Multi-KRAS Cancer Drug Enters Manufacturing Phase with Industry Giant Catalent - Stock Titan
Lisata Therapeutics talks ADC breakthrough with Catalent – ICYMI - Proactive financial news
Lisata Therapeutics announces research license with Catalent - MSN
Lisata Therapeutics CMO discusses potential for certepetide under Catalent license agreement - Proactive financial news
Lisata, Catalent partner for cancer drug research - Investing.com
Lisata, Catalent partner for cancer drug research By Investing.com - Investing.com South Africa
Lisata Therapeutics (LSTA) Partners with Catalent on Preclinical Study | LSTA Stock News - GuruFocus
Lisata Therapeutics Announces Research License with Catalent - GlobeNewswire
Lisata Therapeutics, Inc. Announces Research License with Catalent, Inc - marketscreener.com
Catalent Announces the Appointment of David Schaffer to Biologics Advisory Board - marketscreener.com
Catalent's Journey Of Continuous Improvement For CSV Excellence - Bioprocess Online
Trump’s Tariff Threat Sparks Race to Find US Drug Manufacturers - Yahoo Finance
Jupiter Neurosciences, Catalent Partner to Produce JOTROL Softgels for Upcoming Trial - Contract Pharma
CRDMO Market Research 2025: A Highly Competitive $328 Billion Market by 2029 with Lonza Group, WuXi, Catalent, Sai Life Sciences, Syngene, Jubilant Biosys, and Thermo Fisher Scientific Leading - Yahoo Finance
Unit Dose Manufacturing Industry Report 2025-2030: Market to Cross $150.6 Billion Led by Catalent, Unither Pharmaceuticals, and Thermo Fisher Scientific - Yahoo Finance
Global Cell and Gene Therapy Manufacturing Market to Reach ~USD 10 Billion by 2032 | DelveInsight - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Catalent, Inc. (CTLT) Investigation - ACCESS Newswire
Healthcare CMO Market Projected To Witness Substantial Growth, 2025-2032: Lonza Group, Catalent, Inc., Aenova - EIN News
Per-Encounter Medical Market to Witness Remarkable Growth with Catalent Inc., Smiths Medical Inc., Cardinal Health - openPR
Catalent announces new board appointments - ROI-NJ
Catalent Appoints Susan Mahony, Marie-France Tschudin and Tim Walbert to its Board of Directors - citybiz
Catalent Announces New Board Appointments - Business Wire
Novo to grow Catalent? Rumor mill spins amid Trump tariff threat - BioProcess Insider
Jupiter Neurosciences partners with Catalent for Parkinson's trial - MSN
Ardena Acquires Catalent’s Drug Product Manufacturing Facility in Somerset, NJ - Contract Pharma
Ardena Completes Acquisition of Advanced Drug Product Manufacturing Facility from Catalent and Expands Bioanalytical Services in North America - Yahoo Finance
Jupiter Neurosciences Partners With Catalent For Parkinson's JOTROL Trial Production - Nasdaq
Jupiter Neurosciences Signs Manufacturing Deal With Catalent Pharma for Jotrol Softgel Capsules - Marketscreener.com
Jupiter Neurosciences Partners with Catalent to Produce JOTROL Softgels for Upcoming Clinical Trial - Contract Pharma
Jupiter Neurosciences partners with Catalent for Parkinson's trial By Investing.com - Investing.com South Africa
Jupiter Neurosciences Announces JOTROL Manufacturing Agreement with Catalent to Support Phase 2a Parkinson's Trial - The Manila Times
Jupiter Neurosciences Announces JOTROL Manufacturing - GlobeNewswire
Major Breakthrough: New Parkinson's Drug Manufacturing Deal Could Fast-Track Treatment for 10M Patients - StockTitan
How Novo’s Acquisition Of Catalent Cleared European Regulators - Citeline
Catalent (CTLT) to Report Q2 Earnings: What's in the Cards? - MSN
Catalent (NYSE:CTLT) Now Covered by StockNews.com - Defense World
Pace Life Sciences Expands Capacity and Capability With Acquisition of Catalent’s Analytical Services Laboratory in Research Triangle Park - ACCESS Newswire
Catalent's Award-Winning Innovations and Community Engagement Initiatives - Pharmaceutical Technology
Catalent to make CAR-T for Galapagos; Kindeva gets $129M for nerve agent antidote - Endpoints News
Catalent backs decentralised manufacture of Galapagos’ CAR-T therapy - MSN
Catalent to further expand Galapagos’ decentralized CAR-T manufacturing network in US - Indian Pharma Post
Catalent to support Galapagos’ decentralized cell therapy approach - The Pharma Letter
Catalent to Support Galapagos’ Decentralized CAR-T Therapy Trials - Contract Pharma
Catalent Inc (CTLT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.06%
자본화:
|
볼륨(24시간):